Results 21 to 30 of about 35,624 (244)

Is There a “Blind Spot” in Point-of-Care Testing for Residual Heparin After Cardiopulmonary Bypass? A Prospective, Observational Cohort Study

Clinical and Applied Thrombosis/Hemostasis, 2020
Identifying the cause of a bleeding complication after cardiac surgery can be crucial. This study sought to clarify whether the application of unprocessed autologous pump blood influences anti-factor Xa activity after cardiac surgery and evaluated 2 ...
Saskia Wand MD, Daniel Heise MD, Nadine Hillmann MD, Christian Bireta MD, Anselm Bräuer MD, Nicolas von Ahsen MD, Michael Quintel MD   +6 more
doaj   +1 more source

Oral Direct Factor Xa Inhibitors [PDF]

Circulation Research, 2012
Vitamin K antagonists, such as warfarin, have been the mainstay of oral anticoagulation for many decades. Although effective, warfarin has numerous limitations, including a variable dose requirement from patient to patient because of differences in dietary vitamin K intake, common genetic polymorphisms, and multiple drug interactions that affect its ...
Calvin H, Yeh, James C, Fredenburgh, Jeffrey I, Weitz   +2 more
openaire   +2 more sources

Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors

Molecules, 2016
The geometries and energies of factor Xa inhibitors edoxaban, eribaxaban, fidexaban, darexaban, letaxaban, and the dual factor Xa and thrombin inhibitors tanogitran and SAR107375 in both the gas-phase and aqueous solution were studied using the Becke3LYP/
Milan Remko, Anna Remková, Ria Broer
doaj   +1 more source

Prediction of inhibition constants of (R)-3-amidinophenylalanine inhibitors toward factor Xa by 2D-QSAR model

Vietnam Journal of Science, Technology and Engineering, 2022
A coagulation cascade forms through proteolytic reactions and involves different factors. There are two coagulation pathways, including intrinsic and extrinsic mechanisms, which converge by the formation of factor Xa.
Thi Bich Van Pham, Minh Hao Hoang
doaj   +1 more source

Pharmacist recommendations for prophylactic enoxaparin monitoring and dose adjustment in trauma patients admitted to a surgical intensive care unit

Pharmacy Practice, 2019
Background: There is limited information describing pharmacist participation in prophylactic enoxaparin monitoring in the surgical intensive care unit (SICU).
Scrimenti A, Seabury RW, Miller CD, Ruangvoravat L, Darko W, Probst LA, Cwikla GM   +6 more
doaj   +1 more source

The Impact of Continuous Veno-Venous Hemodiafiltration on the Efficacy of Administration of Prophylactic Doses of Enoxaparin: A Prospective Observational Study

Pharmaceuticals, 2023
Background: Critically ill patients frequently require continuous renal replacement therapy (CRRT). During CRRT, particles up to 10 kDa in size, such as enoxaparin, may be removed. The aim of this study was to determine if patients receiving prophylactic
Aleksander Aszkiełowicz, Karol P. Steckiewicz, Michał Okrągły, Magdalena A. Wujtewicz, Radosław Owczuk   +4 more
doaj   +1 more source

Assessment of anti-factor Xa activity in critically ill COVID-19 patients receiving three different anticoagulation regimens

SAGE Open Medicine, 2021
Introduction: Critically ill COVID-19 patients are at increased risk of thrombosis with an enhanced risk of bleeding. We aimed to explore the role of anti-factor Xa levels in optimizing the high-intensity anticoagulation’s safety and efficacy and finding
Mohammed A Hamad, Shereen A Dasuqi, Aamer Aleem, Rasha A Omran, Rakan M AlQahtani, Fahad A Alhammad, Abdulaziz H Alzeer   +6 more
doaj   +1 more source

Factor Xa Inhibitors [PDF]

, 2016
Factor Xa represents an attractive target for antithrombotic drugs as blockade of factor Xa permits inhibition of both the extrinsic and intrinsic coagulation pathways. Several factor Xa inhibitors, such as rivaroxaban, apixaban and edoxaban, have been approved for certain conditions, and are also in clinical development for other indications.
Eduard Shantsila, Gregory YH Lip
openaire   +1 more source

Reduced anticoagulation strategy is associated with a lower incidence of intracerebral hemorrhage in COVID-19 patients on extracorporeal membrane oxygenation

Intensive Care Medicine Experimental, 2023
Background Optimal anticoagulation strategies for COVID-19 patients with the acute respiratory distress syndrome (ARDS) on venovenous extracorporeal membrane oxygenation (VV ECMO) remain uncertain.
Daniel A. Hofmaenner, David Furfaro, Lennart C. Wild, Pedro David Wendel-Garcia, Elias Baedorf Kassis, Ameeka Pannu, Tobias Welte, Rolf Erlebach, Klaus Stahl, Edward Wilson Grandin, Christian Putensen, Reto A. Schuepbach, Shahzad Shaefi, Sascha David, Benjamin Seeliger, Christian Bode, for the BonHanZA study group   +16 more
doaj   +1 more source

Efficacy and Toxicity of Factor Xa Inhibitors

Journal of Pharmacy & Pharmaceutical Sciences, 2013
Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a public health priority.
Maryna Bondarenko, Christophe Curti, Marc Montana, Pascal Rathelot, Patrice Vanelle   +4 more
doaj   +1 more source